EPIC Act of 2025
Latest action · Mar 4, 2025 Read twice and referred to the Committee on Finance.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMar 4, 2025
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025
This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.
The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.
The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation beginning in 2028.
Cosponsors 7
Members who signed on, in the order they did. Signatures ran from Mar 4, 2025 to Apr 29, 2025; 4 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-OK | James Lankford | Original | Mar 4, 2025 |
| R-TN | Marsha Blackburn | Original | Mar 4, 2025 |
| R-MT | Steve Daines | Original | Mar 4, 2025 |
| R-NC | Ted Budd | Original | Mar 4, 2025 |
| R-UT | John R. Curtis | Apr 10, 2025 | |
| R-IN | Jim Banks | Apr 29, 2025 | |
| R-KS | Roger Marshall | Apr 29, 2025 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| Senate | Finance Committee | Referred Mar 4, 2025 |
Actions 2
Everything that happened, newest first.
- Mar 4, 2025Introduced in Senate
- Mar 4, 2025Read twice and referred to the Committee on Finance.
Titles 3
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- A bill to amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
- Short Title(s) as Introduced
- EPIC Act of 2025
- Ensuring Pathways to Innovative Cures Act of 2025
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Mar 4, 2025Introduced in Senate
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.